NTX-001
Upper Extremity Transected Nerves Requiring Surgical Repair
Key Facts
About Neuraptive Therapeutics
Neuraptive Therapeutics is a private, clinical-stage biotech focused on revolutionizing the repair of severed peripheral nerves. Its core technology is a PEG-fusion system in-licensed from the University of Texas at Austin, which is the basis of its lead candidate, NTX-001, currently in Phase 3 trials for upper extremity nerve injuries. The company is pursuing a multi-product strategy that also includes a specialized drug delivery device and proprietary microsurgical instruments, targeting a significant and well-reimbursed global market opportunity estimated at over $5.5 billion.
View full company profileAbout Neuraptive Therapeutics
Neuraptive Therapeutics is a private, clinical-stage biotech focused on revolutionizing the repair of severed peripheral nerves. Its core technology is a PEG-fusion system in-licensed from the University of Texas at Austin, which is the basis of its lead candidate, NTX-001, currently in Phase 3 trials for upper extremity nerve injuries. The company is pursuing a multi-product strategy that also includes a specialized drug delivery device and proprietary microsurgical instruments, targeting a significant and well-reimbursed global market opportunity estimated at over $5.5 billion.
View full company profile